ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer

医学 前列腺切除术 前列腺癌 泌尿科 临床终点 安慰剂 前列腺特异性抗原 前列腺 新辅助治疗 活检 随机对照试验 内科学 肿瘤科 癌症 病理 乳腺癌 替代医学
作者
Gaëtan Devos,Lorenzo Tosco,Marcella Baldewijns,Thomas Gevaert,Karolien Goffin,Valentin Petit,Cindy Mai,Annouschka Laenen,Yannic Raskin,Carl Van Haute,Lieven Goeman,Gert De Meerleer,Charlien Berghen,Wout Devlies,Frank Claessens,Hendrik Van Poppel,Wouter Everaerts,Steven Joniau
出处
期刊:European Urology [Elsevier BV]
卷期号:83 (6): 508-518 被引量:48
标识
DOI:10.1016/j.eururo.2022.09.009
摘要

High-risk prostate cancer (PCa) patients have a high risk of biochemical recurrence and metastatic progression following radical prostatectomy (RP). To determine the efficacy of neoadjuvant degarelix plus apalutamide before RP compared with degarelix with a matching placebo. ARNEO was a randomized, placebo-controlled, phase II neoadjuvant trial before RP performed between March 2019 and April 2021. Eligible patients had high-risk PCa and were amenable to RP. Patients were randomly assigned at a 1:1 ratio to degarelix (240–80–80 mg) + apalutamide (240 mg/d) versus degarelix + matching placebo for 3 mo followed by RP. Prior to and following neoadjuvant treatment, pelvic 18F-PSMA-1007 positron emission tomography (PET)/magnetic resonance imaging (MRI) was performed. The primary endpoint was the difference in proportions of patients with minimal residual disease (MRD; = residual cancer burden (RCB) ≤0.25 cm3 at final pathology). Secondary endpoints included differences in prostate-specific antigen responses, pathological staging, and change in TNM stage on prostate-specific membrane antigen (PSMA) PET/MRI following hormonal treatment. Biomarkers (immunohistochemical staining on prostate biopsy [PTEN, ERG, Ki67, P53, GR, and PSMA] and PSMA PET/MRI-derived characteristics) associated with pathological response (MRD and RCB) were explored. Patients were randomized to neoadjuvant degarelix + apalutamide (n = 45) or degarelix + matching placebo (n = 44) for 12 wk and underwent RP. Patients in the degarelix + apalutamide arm achieved a significantly higher rate of MRD than those in the control arm (38% vs 9.1%; relative risk [95% confidence interval] = 4.2 [1.5–11], p = 0.002). Patients with PTEN loss in baseline prostate biopsy attained significantly less MRD (11% vs 43%, p = 0.002) and had a higher RCB at final pathology (1.6 vs 0.40 cm3, p < 0.0001) than patients without PTEN loss. Following neoadjuvant hormonal therapy, PSMA PET–estimated tumor volumes (1.2 vs 2.5 ml, p = 0.01) and maximum standardized uptake value (SUVmax; 4.3 vs 5.7, p = 0.007) were lower in patients with MRD than in patients without MRD. PSMA PET–estimated volume and PSMA PET SUVmax following neoadjuvant treatment correlated significantly with RCB at final pathology (both p < 0.001). In high-risk PCa patients, neoadjuvant degarelix plus apalutamide prior to RP results in a significantly improved pathological response (MRD and RCB) compared with degarelix alone. Our trial results provide a solid hypothesis-generating basis for neoadjuvant phase 3 trials, which are powered to detect differences in long-term oncological outcome following neoadjuvant androgen receptor signaling inhibitor therapy. In this study, we looked at the difference in pathological responses in high-risk prostate cancer patients treated with degarelix plus apalutamide or degarelix plus matching placebo prior to radical prostatectomy. We demonstrated that patients treated with degarelix plus apalutamide achieved a significantly better tumor response than patients treated with degarelix plus matching placebo. Long-term follow-up is required to determine whether improved pathological outcome translates into better oncological outcomes.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
roclie完成签到,获得积分10
刚刚
文静的如娆完成签到,获得积分10
1秒前
2秒前
Yy完成签到,获得积分10
3秒前
4秒前
4秒前
4秒前
dengyan完成签到,获得积分10
5秒前
CodeCraft应助汪汪采纳,获得10
5秒前
我是老大应助刻苦的书竹采纳,获得10
6秒前
智慧爷爷发布了新的文献求助10
6秒前
酷波er应助lw777采纳,获得10
6秒前
岁月如歌发布了新的文献求助10
8秒前
bin完成签到,获得积分10
10秒前
10秒前
很好完成签到,获得积分10
11秒前
小郝已读博完成签到 ,获得积分10
11秒前
11秒前
Self-made完成签到,获得积分10
11秒前
12秒前
13秒前
14秒前
岁月如歌完成签到,获得积分10
15秒前
16秒前
joey完成签到,获得积分10
17秒前
wei完成签到 ,获得积分10
18秒前
miaojuly发布了新的文献求助10
19秒前
19秒前
研友_LXjjOZ发布了新的文献求助150
19秒前
20秒前
21秒前
22秒前
坚定馒头完成签到,获得积分10
22秒前
23秒前
23秒前
星星应助科研通管家采纳,获得30
25秒前
y924758705完成签到,获得积分20
25秒前
打打应助科研通管家采纳,获得10
25秒前
坦率的匪应助科研通管家采纳,获得10
25秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3988868
求助须知:如何正确求助?哪些是违规求助? 3531255
关于积分的说明 11253071
捐赠科研通 3269858
什么是DOI,文献DOI怎么找? 1804822
邀请新用户注册赠送积分活动 881994
科研通“疑难数据库(出版商)”最低求助积分说明 809035